2023 World Conference on Lung Cancer (Posters)-EP07.04. Study on the Regulatory Mechanism of OM-85 BV on the Immune Microenvironment of Clinical Early-stage Lung Adenocarcinoma

EP07.04. Study on the Regulatory Mechanism of OM-85 BV on the Immune Microenvironment of Clinical Early-stage Lung Adenocarcinoma - PDF(Slides)

Back to course

Pdf Summary

OM-85 Broncho-Vaxom (BV) is a bacterial lysis product that has immunomodulatory effects. In this study, the researchers investigated the effects and mechanisms of OM-85 BV on early-stage lung adenocarcinoma. They established mouse models that closely resembled human lung nodules and adenocarcinoma. The mice were divided into three groups: a benign nodule control group, an early-stage lung adenocarcinoma control group, and an OM-85 BV intervention group. The researchers analyzed the immune microenvironment by observing tumor growth, histopathology, immunofluorescence, and distribution of immune cells using single-cell sequencing and spatial transcriptometechniques. They also performed multiple immunofluorescence analyses in a clinical cohort. <br /><br />The results showed that tumor growth and levels of immune cells and factors in the OM-85 BV intervention group were similar to those in the benign nodule control group, but higher than in the early lung adenocarcinoma control group. This suggests that OM-85 BV may inhibit the progression of early lung adenocarcinoma by regulating the number and activity of T cells, NK cells, and macrophages. <br /><br />In conclusion, OM-85 BV could be a low-cost alternative for inhibiting the progression of early-stage lung adenocarcinoma through simple oral administration.

Asset Subtitle

Dawei Yang

Meta Tag

Speaker Dawei Yang

Topic Early-Stage NSCLC: Progress in Pathology

Keywords

OM-85 Broncho-Vaxom

bacterial lysis product

immunomodulatory effects

lung adenocarcinoma

mouse models

immune microenvironment

tumor growth

histopathology

immune cells

oral administration